Patient literacy and awareness of medicine safety

Marissa See\(^a\), Belinda E. Butcher\(^{b,c}\) and Alex Banh\(^d\)

\(^a\)Bayer (SouthEast Asia) Limited, Singapore City, Singapore, \(^b\)WriteSource Medical Pty Ltd, Lane Cove, NSW, \(^c\)School of Medical Science, University of New South Wales, UNSW Sydney, NSW and \(^d\)Bayer Australia Limited, Pymble, NSW, Australia

**Keywords**
adverse reactions; consumer; medication; patients; pharmacovigilance

**Correspondence**
Alex Banh, Bayer Australia Limited, 875 Pacific Highway, Pymble, NSW 2073, Australia.
E-mail: alex.banh@bayer.com

Received August 7, 2019
Accepted August 5, 2020
doi: 10.1111/ijpp.12671

**Abstract**

**Objective** To assess public understanding of medicine safety, approach to risks and preferences in accessing safety information.

**Methods** Qualitative data were obtained from an online survey (\(n = 1079\)) covering four major themes around side effects and risks of medicines: willingness to accept side effects of medications, information seeking, sufficiency of information and understanding pharmacovigilance process. Comparisons were made for age, gender and social/financial status.

**Key findings** Most respondents acknowledged medications were associated with side effects. If side effects were experienced, most (73%) would seek advice from their doctor or pharmacist. Four in 10 respondents felt doctors and pharmacists do not provide sufficient information about medications, even though many (47%) relied on their doctor to provide this. Although 51% felt that pharmaceutical companies were already providing enough information to patients, 95% responded that extra effort could still be made. Two-thirds of the respondents felt it was the companies’ responsibility to educate doctors and pharmacists so they could pass the information on, even though younger respondents preferred direct communication to patients compared to older respondents (<24 years, 36% versus >65 years, 10%; \(P < 0.001\)). Men were more willing to accept risks, while women were more likely to seek information about their medicines. Understanding of the role of pharmaceutical companies and government in maintaining the safety of medicines was generally poor.

**Conclusions** There is an ongoing need for consumer education regarding medicine safety. Doctors and pharmacists remain the more trusted source of information. Pharmaceutical companies play an important role in ensuring such information is both accessible and accurate.

**Introduction**

Patient safety is paramount both during pharmaceutical development and once the medicine becomes available on the market. However, how a patient assesses the risks and benefits of their prescribed medication is poorly understood. Furthermore, patients may lack awareness of the roles pharmaceutical companies and governmental agencies play in ensuring the safety of medicines, and therefore why it is important to report side effects experienced when taking their medicines.

**Healthcare professionals**

The prescribing doctor and the dispensing pharmacist are important sources of information about the safety of medicines.\(^{[1,2]}\) In general, patients have a positive attitude towards health information provided by pharmacists\(^{[3,4]}\) and their doctor,\(^{[5]}\) even if some patients may not be aware that pharmacists play an important role in providing such advice.\(^{[1]}\)

**Package inserts**

Manufacturers provide package inserts with all prescription medicines, and many pharmacist-only medicines, which provide information about the medicine and its use. The quality of information contained in these leaflets varies across different countries, depending on their regulatory requirements,\(^{[6]}\) and patients may find these inserts
difficult to understand. It is unclear how much patients rely on this as a source of information.

Social media and digital platforms

Since the advent of social media, people have been increasingly accessing information via digital platforms, including information regarding medicines and their health. A review of current literature by Househ et al. described the potential value of social media as a technology to empower and engage patients to improve health, amongst other potential benefits, however also cited little evidence in academic literature to show actual benefits. Misinformation was one of the challenges highlighted as a potential threat to patients.

Given the various potential sources of information, and our lack of understanding on what patients opinions are with regard to safety information, we conducted a survey of consumers to determine attitudes towards medicine safety and information. The purpose of this survey was to investigate consumer understanding of how the safety of medicines is monitored and to determine how patients assess the risks associated with medicines, and how they prefer to receive safety information, in order to identify potential actions to help improve patient safety.

Methods

Qualitative approach

We assumed there was no one ‘single objective reality’ and thus used an interpretivist approach to this research. Qualitative data were obtained from an online survey administered to members of a panel of Australian individuals between 20 and 23 September 2018. These individuals had previously agreed to take part in ongoing surveys. At the time of their recruitment onto the panel, individuals provided written informed consent. This study was conducted in accordance with industry standards and the standards set out in the Australian Market and Social Research Society Code of Professional Behaviour.

Participants

Potential participants aged 18 years or older were selected randomly from the pool of more than 100 000 available panellists from the YouGov Panellist Omnibus. These potential participants were emailed an invitation to the survey and were provided with a link directing them to the survey. The planned sample size was 1000 participants, with quotas put on the age, sex and region of participants to reflect the broader Australian population. Potential participants were repeatedly approached until the minimum sample size was met, and then, the survey was closed.

Survey instrument

This survey was conducted by YouGov Galaxy Online Omnibus. The survey instrument included nine questions on the participant’s attitudes towards medication and pharmacovigilance (Table S1), with additional questions to determine demographic segments (Tables 1 and 2, Question 10). The survey covered four major themes around side effects and risks of medicines: willingness to accept side effects of medications, information seeking, sufficiency of information and understanding pharmacovigilance process. Items included single-select, multi-select and a mixture of fixed and exclusive responses. In order to minimise bias in response, the order of possible responses was randomly presented.

Statistical considerations

Responses are presented overall and stratified by sex, age, generation, marital status, children, work status, state, location, household income, whether the participant had previously taken a prescription medicine and whether they had been a carer for someone taking a prescription

Table 1

| Demographic                          | Surveyed population, n (%) | Weighting based on inflated 2016 ABS data |
|--------------------------------------|----------------------------|------------------------------------------|
| Sex                                  |                            |                                          |
| Male                                 | 533 (49.4)                 | 48.8                                     |
| Female                               | 546 (50.6)                 | 51.2                                     |
| Age, years                           |                            |                                          |
| 18–24                                | 102 (9.5)                  | 11.8                                     |
| 25–34                                | 197 (18.3)                 | 18.5                                     |
| 35–49                                | 315 (29.2)                 | 26                                       |
| 50–64                                | 261 (24.2)                 | 23.5                                     |
| 65+                                  | 204 (18.9)                 | 20.2                                     |
| Has children                         |                            |                                          |
| Yes                                  | 345 (32.0)                 | 30.4                                     |
| No                                   | 734 (68.0)                 | 69.6                                     |
| State                                |                            |                                          |
| New South Wales                      | 342 (31.7)                 | 32.1                                     |
| Victoria                             | 263 (24.4)                 | 25.6                                     |
| Queensland                           | 225 (20.9)                 | 19.9                                     |
| South Australia                      | 102 (9.5)                  | 7.3                                      |
| Western Australia                    | 102 (9.5)                  | 10.5                                     |
| Other states/territories             | 45 (4.2)                   | 4.6                                      |
| Income category, AUD$                |                            |                                          |
| <$50K                                | 363 (33.6)                 | 34.8                                     |
| $50–99K                              | 331 (30.7)                 | 30.3                                     |
| $100–149K                            | 184 (17.1)                 | 16.3                                     |
| $150K+                               | 83 (7.7)                   | 7.5                                      |
Table 2  Survey results overall, and by sex, age and household income

| Total  | Sex       | Age       | Household Income |
|--------|-----------|-----------|------------------|
|        | Base      | Male      | Female | 18-24 | 25-34 | 35-49 | 50-64 | 65+ | <$50k | $50K-$99K | $100K-$149K | $150+ |
| 1. When taking any type of medicine there is a risk of side effects. For each of the following, in your opinion, please say whether the risk of side effects is acceptable or not acceptable? If the side effects from a medicine are only likely to affect a very small proportion of the population: Unweighted base 1079 | 533 | 546 | 102 | 197 | 315 | 261 | 204 | 363 | 331 | 184 | 83 |
| Base   | 19432 | 9477 | 9955 | 2296 | 3594 | 5049 | 4570 | 3923 | 6762 | 5891 | 3169 | 1458 |
| Acceptable | 47% | 52% | 43% | 49% | 46% | 47% | 47% | 48% | 43% | 46% | 53% | 60% |
| Not acceptable | 22% | 23% | 21% | 24% | 23% | 21% | 22% | 20% | 24% | 23% | 16% | 20% |
| It depends | 31% | 26% | 36% | 27% | 31% | 32% | 32% | 32% | 31% | 31% | 20% | 20% |
| If the medicine is used to treat a serious condition, such as cancer: Unweighted base 1079 | 533 | 546 | 102 | 197 | 315 | 261 | 204 | 363 | 331 | 184 | 83 |
| Base   | 19432 | 9477 | 9955 | 2296 | 3594 | 5049 | 4570 | 3923 | 6762 | 5891 | 3169 | 1458 |
| Acceptable | 64% | 70% | 59% | 79% | 66% | 58% | 62% | 65% | 62% | 65% | 73% | 72% |
| Not acceptable | 11% | 12% | 10% | 6% | 14% | 16% | 11% | 7% | 11% | 11% | 11% | 18% |
| It depends | 24% | 18% | 30% | 15% | 20% | 27% | 27% | 28% | 27% | 24% | 16% | 10% |
| If it was a new type of medicine: Unweighted base 1079 | 533 | 546 | 102 | 197 | 315 | 261 | 204 | 363 | 331 | 184 | 83 |
| Base   | 19432 | 9477 | 9955 | 2296 | 3594 | 5049 | 4570 | 3923 | 6762 | 5891 | 3169 | 1458 |
| Acceptable | 28% | 32% | 24% | 41% | 35% | 28% | 23% | 19% | 24% | 31% | 28% | 42% |
| Not acceptable | 25% | 24% | 25% | 17% | 27% | 25% | 26% | 24% | 26% | 25% | 20% | 23% |
| It depends | 48% | 44% | 51% | 42% | 37% | 47% | 52% | 56% | 49% | 44% | 53% | 35% |
| Non-prescription medicine, such as paracetamol: Unweighted base 1079 | 533 | 546 | 102 | 197 | 315 | 261 | 204 | 363 | 331 | 184 | 83 |
| Base   | 19432 | 9477 | 9955 | 2296 | 3594 | 5049 | 4570 | 3923 | 6762 | 5891 | 3169 | 1458 |
| Acceptable | 40% | 42% | 39% | 43% | 40% | 35% | 41% | 43% | 43% | 37% | 38% | 48% |
| Not acceptable | 37% | 38% | 35% | 36% | 39% | 39% | 36% | 35% | 32% | 40% | 41% | 36% |
| It depends | 23% | 20% | 26% | 21% | 21% | 26% | 23% | 22% | 24% | 23% | 21% | 16% |
| Medicine for children: Unweighted base 1079 | 533 | 546 | 102 | 197 | 315 | 261 | 204 | 363 | 331 | 184 | 83 |
| Base   | 19432 | 9477 | 9955 | 2296 | 3594 | 5049 | 4570 | 3923 | 6762 | 5891 | 3169 | 1458 |
| Acceptable | 21% | 25% | 17% | 37% | 29% | 22% | 15% | 12% | 19% | 22% | 20% | 36% |
| Not acceptable | 45% | 46% | 45% | 32% | 42% | 43% | 48% | 55% | 47% | 47% | 43% | 37% |
| It depends | 33% | 29% | 38% | 31% | 29% | 35% | 37% | 33% | 34% | 31% | 37% | 27% |
| 2. Who is the first person you speak to or contact when you experience a side effect from medicine? Please select one option only Unweighted base 1079 | 533 | 546 | 102 | 197 | 315 | 261 | 204 | 363 | 331 | 184 | 83 |
| Base   | 19432 | 9477 | 9955 | 2296 | 3594 | 5049 | 4570 | 3923 | 6762 | 5891 | 3169 | 1458 |
| My doctor or pharmacist | 73% | 68% | 77% | 51% | 57% | 65% | 86% | 94% | 80% | 70% | 72% | 60% |
| Discuss it on social media, such as Facebook or online forums | 2% | 3% | 2% | 3% | 7% | 2% | 1% | 1% | 1% | 4% | 2% | 3% |
| Family members or friends | 19% | 20% | 18% | 36% | 27% | 25% | 10% | 3% | 13% | 20% | 23% | 23% |
Table 2  Continued

| Total | Sex | Age | Household Income |
|-------|-----|-----|------------------|
|       | Base | Male | Female | 18-24 | 25-34 | 35-49 | 50-64 | 65+ | <$50k | $50K- $99K | $100K- $149K | $150K+ |
| Contact the manufacturer | 2% | 3% | 1% | 3% | 4% | 1% | 2% | — | 2% | 2% | — | 5% |
| Don’t know | 4% | 6% | 3% | 7% | 6% | 6% | 2% | 2% | 3% | 4% | 3% | 9% |

3 What do you think the companies that make medicine do when someone contacts them to report a side effect they have experienced after taking their medicine? Please select all that apply

| Unweighted base | 1079 | 533 | 546 | 102 | 197 | 315 | 261 | 204 | 363 | 331 | 184 | 83 |
| Base | 19432 | 9477 | 9955 | 2296 | 3594 | 5049 | 4570 | 3923 | 6762 | 5891 | 3169 | 1458 |

| Contact the manufacturer | 28% | 30% | 25% | 31% | 32% | 25% | 26% | 27% | 28% | 29% | 24% | 36% |
| Use the information to make the medication more safe | 21% | 23% | 19% | 23% | 25% | 21% | 17% | 20% | 22% | 18% | 25% | 24% |
| Inform the government body that regulates medicines | 29% | 31% | 27% | 32% | 38% | 30% | 23% | 25% | 30% | 30% | 33% | 32% |
| Undertake further research to understand the problem | 11% | 11% | 10% | 12% | 14% | 13% | 8% | 6% | 11% | 11% | 10% | 16% |
| Withdraw the medicine from the market | 39% | 36% | 41% | 38% | 42% | 36% | 40% | 38% | 37% | 41% | 42% | 39% |

| Don’t know | 11% | 9% | 13% | 10% | 13% | 14% | 10% | 7% | 10% | 12% | 11% | 11% |

4. Here is an image of a typical information sheet that is supplied with prescription medicine. In situations where you choose not to read the information sheets, please select the reasons for this from the list below. Please select all that apply

| Unweighted base | 1079 | 533 | 546 | 102 | 197 | 315 | 261 | 204 | 363 | 331 | 184 | 83 |
| Base | 19432 | 9477 | 9955 | 2296 | 3594 | 5049 | 4570 | 3923 | 6762 | 5891 | 3169 | 1458 |

| The writing is too small | 34% | 38% | 31% | 30% | 38% | 30% | 40% | 33% | 31% | 38% | 36% | 31% |
| The risk of side effects is quite low | 16% | 18% | 14% | 15% | 15% | 17% | 14% | 17% | 16% | 16% | 16% | 25% |
| My doctor would have advised me of the main points | 47% | 49% | 45% | 48% | 44% | 41% | 47% | 55% | 48% | 43% | 50% | 53% |
| If I’m taking a medicine I have used before | 43% | 39% | 48% | 46% | 41% | 40% | 48% | 44% | 41% | 42% | 50% | 47% |
| I don’t think I need to | 11% | 9% | 13% | 10% | 13% | 14% | 10% | 7% | 10% | 12% | 11% | 11% |
| I find them too hard to understand | 22% | 27% | 16% | 21% | 27% | 20% | 23% | 18% | 19% | 23% | 22% | 22% |
| It’s just something provided by the manufacturer to cover themselves | 28% | 33% | 23% | 22% | 28% | 31% | 30% | 26% | 23% | 32% | 32% | 24% |
| None of the above | 10% | 9% | 11% | 8% | 8% | 12% | 11% | 10% | 11% | 7% | 9% |

5. What is your preferred way of accessing information about your medicine? Please select one option only

| Unweighted base | 1079 | 533 | 546 | 102 | 197 | 315 | 261 | 204 | 363 | 331 | 184 | 83 |
| Base | 19432 | 9477 | 9955 | 2296 | 3594 | 5049 | 4570 | 3923 | 6762 | 5891 | 3169 | 1458 |

| From the package leaflet that comes with the medicine | 20% | 16% | 24% | 22% | 20% | 24% | 18% | 16% | 20% | 21% | 17% | 17% |
| Verbally from doctor or pharmacist | 53% | 52% | 53% | 43% | 42% | 41% | 63% | 71% | 54% | 49% | 59% | 50% |
| Online from the company website | 5% | 5% | 6% | 6% | 7% | 6% | 4% | 3% | 4% | 6% | 5% | 6% |
| Internet search, such as Google or Wikipedia | 14% | 15% | 13% | 11% | 17% | 19% | 12% | 9% | 13% | 16% | 11% | 15% |
| Social media such as Twitter, Facebook or user forums | 2% | 3% | 1% | 4% | 3% | 2% | 1% | — | 2% | 3% | 2% | — |
| Friends and family | 3% | 5% | 2% | 7% | 7% | 4% | 0% | 0% | 3% | 2% | 6% | 8% |
| None of the above | 3% | 4% | 2% | 7% | 3% | 5% | 1% | — | 4% | 2% | 1% | 3% |

6. What do you think the government does to keep medicines safe? Please select all that apply

| Unweighted base | 1079 | 533 | 546 | 102 | 197 | 315 | 261 | 204 | 363 | 331 | 184 | 83 |
| Base | 19432 | 9477 | 9955 | 2296 | 3594 | 5049 | 4570 | 3923 | 6762 | 5891 | 3169 | 1458 |
Table 2  Continued

| Total | Sex | Age | Household Income |  |
|-------|-----|-----|------------------|---|
|       | Base| Male| Female | 18-24 | 25-34 | 35-49 | 50-64 | 65- | $<50K | $50K-99K | $100K-149K | $150K+ |
|       |     |     |        |       |       |       |       |     |       |       |           |           |
| They check all the research and only allow 100% safe medicines to have a license | 29% | 30% | 27% | 29% | 29% | 26% | 27% | 34% | 28% | 35% | 24% | 23% |
| They check all the research and give a license if the benefit of the drug is more than the risk of harm | 40% | 38% | 42% | 40% | 39% | 37% | 42% | 42% | 37% | 44% | 36% | 46% |
| They have laws that companies that make medicine have to follow | 56% | 56% | 55% | 62% | 49% | 53% | 57% | 62% | 53% | 58% | 54% | 58% |
| They check up on the companies that make medicine to make sure they are following the law | 32% | 35% | 30% | 37% | 40% | 32% | 29% | 26% | 28% | 39% | 30% | 28% |
| Nothing | 12% | 13% | 11% | 5% | 14% | 13% | 16% | 7% | 14% | 10% | 12% | 5% |

7. Currently, companies that make medicine provide information to patients through a variety of ways, including package information leaflets, patient booklets, medical information hotlines etc. In your opinion, is this sufficient safety information or should they be providing more information about the medicines they produce? Please select one option only

Unweighted base | 1079 | 533 | 546 | 102 | 197 | 315 | 261 | 204 | 363 | 331 | 184 | 83 |
Base | 19432 | 9477 | 9955 | 2296 | 3594 | 5049 | 4570 | 3923 | 6762 | 5891 | 3169 | 1458 |

Already provide sufficient information | 51% | 51% | 51% | 50% | 55% | 50% | 47% | 56% | 52% | 51% | 53% | 59% |
Should provide more information | 34% | 35% | 33% | 31% | 33% | 31% | 39% | 34% | 33% | 35% | 35% | 28% |
Don’t know | 15% | 14% | 16% | 19% | 13% | 13% | 19% | 14% | 11% | 15% | 14% | 12% |

8. Do you think doctors and pharmacists provide patients with sufficient safety information about medicines or should they be providing more information? Please select one option only

Unweighted base | 1079 | 533 | 546 | 102 | 197 | 315 | 261 | 204 | 363 | 331 | 184 | 83 |
Base | 19432 | 9477 | 9955 | 2296 | 3594 | 5049 | 4570 | 3923 | 6762 | 5891 | 3169 | 1458 |

Already provide sufficient information | 48% | 51% | 44% | 41% | 41% | 47% | 47% | 59% | 50% | 44% | 54% | 52% |
Should provide more information | 42% | 40% | 44% | 50% | 46% | 39% | 43% | 35% | 40% | 45% | 39% | 38% |
Don’t know | 10% | 9% | 12% | 9% | 13% | 13% | 9% | 5% | 10% | 12% | 7% | 10% |

9. What do companies that make medicine need to do to ensure patients have all the information needed to make a decision about taking their medicines? Please select one option only

Unweighted base | 1079 | 533 | 546 | 102 | 197 | 315 | 261 | 204 | 363 | 331 | 184 | 83 |
Base | 19432 | 9477 | 9955 | 2296 | 3594 | 5049 | 4570 | 3923 | 6762 | 5891 | 3169 | 1458 |

Education campaigns and social media to inform patients directly | 19% | 20% | 17% | 36% | 30% | 17% | 11% | 10% | 16% | 21% | 21% | 19% |
Educate doctors and pharmacists to inform patients | 67% | 63% | 71% | 49% | 55% | 62% | 78% | 81% | 70% | 65% | 65% | 65% |
No extra effort needed | 9% | 9% | 9% | 9% | 10% | 15% | 6% | 4% | 8% | 8% | 9% |

10. As an adult, have you ever taken or been a carer for someone who has taken medicine prescribed by a doctor? Please select all that apply

Unweighted base | 1079 | 533 | 546 | 102 | 197 | 315 | 261 | 204 | 363 | 331 | 184 | 83 |
Base | 19432 | 9477 | 9955 | 2296 | 3594 | 5049 | 4570 | 3923 | 6762 | 5891 | 3169 | 1458 |

I have taken medicine prescribed by a doctor | 79% | 76% | 82% | 74% | 71% | 77% | 86% | 85% | 78% | 80% | 79% | 78% |
I have been a carer for someone who has taken medicine prescribed by a doctor | 32% | 26% | 37% | 28% | 31% | 33% | 33% | 32% | 30% | 33% | 33% | 35% |
Neither of the above | 13% | 16% | 9% | 14% | 18% | 15% | 8% | 9% | 13% | 14% | 11% | 8% |
of new medications, compared to the willingness of respondents in younger age groups were willing to accept side effects for serious conditions, such as cancer. Males were more willing to accept risks in greater acceptance of side effects for new medications, almost half believed that their doctor would provide sufficient medicines information to patients (Table 2, Question 7), and one in five felt that companies should make more use of education campaigns and social media to inform patients directly.

**Understanding of the pharmacovigilance process**

Generally speaking, respondent understanding of the pharmacovigilance process was poor. Almost four in 10 respondents felt that pharmaceutical companies only followed up on safety information once a certain number of complaints had been received; two in 10 reported they thought pharmaceutical companies did not do anything with the information received (Table 2, Question 3). On the other hand, over a quarter of respondents had confidence that companies used the reported safety information to make medicines safer (28%) and to undertake further research to understand the problem (29%). In terms of government involvement, while most respondents (88%) accepted that governments have a role in assessing the safety of medicine, smaller proportions knew how they achieved this (Table 2, Question 6). For

| Table 2, Question 10 | 13% of respondents having no prior experience of either prescription medication or been a carer for someone who had taken a medicine prescribed by a doctor, with only 13% of respondents having no prior experience of either (Table 2, Question 10).

| Table 2, Question 8 | Four in 10 respondents (42%) felt that doctors and pharmacists do not provide sufficient information about medications (Table 2, Question 8). However, confidence in the role that these health professionals play in information provision increased with increasing age (P < 0.001). Many participants felt that their doctor would provide the necessary information regarding their medication, and felt it was the responsibility of companies to educate their doctor and pharmacist so they could pass the information on (Table 2, Question 9). This was particularly true in older age groups. In comparison, the younger the age group, the more likely they were to prefer educational campaigns targeting patients directly (P < 0.001).

In exploring possible reasons why only one in five respondents used the package information leaflet that comes with medication, almost half believed that their doctor would advise them of the main points, with 43% believing they did not need to if they had taken the medicine before (Table 2, Question 4). One-third of respondents reported that the writing in consumer medicines information sheets was too small to read. Only half of respondents felt that companies provided sufficient medicines information to patients (Table 2, Question 7), and one in five felt that companies should make more use of education campaigns and social media to inform patients directly.
example, just over half (56%) of respondents knew that governments produced legislation that companies have to follow and one-third (32%) knew that governments check up on companies to ensure they are complying with the law. Interestingly, while four out of 10 respondents understood the concept of weighing up the benefit of drug compared to the risk of harm, approximately one-third (29%) of respondents believed that governments only issue a license when a medication is 100% safe. Note that the concept of ‘100% safe’ was subject to interpretation. A small proportion of respondents (12%) believed that the government played no role in keeping medicines safe for the public.

Discussion

Our study has provided a broad overview of patient attitudes to medicine safety information. Much of the research in this field to date has had a single research area focus, for example consumer use of the package insert,[7,9,14] consumer attitudes towards pharmacist-delivered health services and health information[11] or the public perception of the pharmaceutical industry.[15]

Willingness to accept side effects of medication

Our study reinforced that patients do appear to be willing to accept side effects of medication, especially in older age.[5] Perhaps unsurprisingly, their acceptance of adverse effects differed depending on the purpose and intended recipient of the medication. Gender differences in willingness to accept side effects of medications may reflect differences in risk assessment between men and women.[16] However, the interplay between risk assessment and medication aversion are still the subject of much debate.

Information seeking

There appears to be an association between information seeking, concerns about treatment[17] and treatment adherence. Almost three-quarters of respondents in our study reported they would seek advice from their doctor or pharmacist if they experienced a side effect. Others have suggested patients trust their doctor’s advice for general medicine information[18] and for information in the event side effects occur.[5] Our study also showed a clear difference in information seeking behaviour between women and men.

There was interest, particularly in younger people, to access medicines information online. Given the inaccuracies of health information that may be accessed online,[19,20] it is important that processes are in place to educate patients about where appropriate information might be accessed, in order to minimise misinformation.

Sufficiency of information

Respondents expected medicines information to come from healthcare professionals, and some of the responses shows a prevailing level of scepticism about the pharmaceutical industry.

Given the time constraints of medical appointments, healthcare professionals must curate the information provided to patients about possible side effects of medications. Despite this, most patients expect that all information on all possible side effects is delivered by their doctor.[21] From a practical sense, this is unlikely to be possible, so alternative methods of information delivery that compliments the consultation must be considered. Package information leaflets may not provide information on medication side effects at an appropriately accessible level.[9,22–25] Indeed, we may require a tailored approach to information dissemination that takes into account the nature of the side effect, its likelihood and the patient demographics.[14,16,25–27]

Understanding pharmacovigilance process

Our study suggests that there is poor understanding of the regulatory requirements around adverse event reporting, which concords with other reports.[28,29] Respondents typically trusted governments over pharmaceutical companies, which may correlate to a low level of health literacy.[30] There is a need to empower patients to appropriately report side effects of medications.[31] Novel strategies for two-way risk communication using Applications software are being investigated in Europe. To date, there is high interest amongst both healthcare professionals and patients in these systems.[32] Such systems might be particularly beneficial given the complementary nature of information derived from patients and healthcare professionals on the severity and impact of medication side effects,[33] and may provide a simple solution to ‘how’ to report events.

Limitations

This study has some limitations. Firstly, the respondents were a group of people who had enrolled as YouGov panellists. These respondents are likely to have a high level of engagement regardless of the survey topic, and therefore, results may not be generalisable to the entire population. Secondly, it is difficult to determine from the survey results how many of the respondents that may suffer from a chronic health condition, with complex medication needs. Such patients may have a different attitude to medication risk. Finally, hypothesis testing was not
planned *a priori*, and no adjustment for multiple comparisons has been made.

**Conclusion**

This study has provided an overview of patient attitudes towards medication safety in terms of sourcing information, identifying risks and reporting events. There is an ongoing need for patient education in this regard. Given the time constraints of healthcare professionals, there is an opportunity for industry- or government-run education campaigns on medication safety. Such programs could improve health literacy and build trust between the public and the pharmaceutical industry. Patient segmentation should also be considered in order to have a more targeted and patient-centric approach towards increasing the impact of such programs.

**Declarations**

**Conflict of interest**

The Author(s) declare(s) that they have no conflicts of interest to disclose.

**References**

1. Krska J, Morecroft CW. Views of the general public on the role of pharmacy in public health. *J Pharm Health Serv Res* 2010; 1: 33–38.
2. O’Donovan B et al. Use of information sources regarding medicine side effects among the general population: a cross-sectional survey. *Prim Health Care Res Dev* 2019; 20: e153.
3. Teh R, Chen T, Krass I. Consumer perspectives of pharmacist-delivered health information and screening services. *Int J Pharm Pract* 2001; 9: 261–267.
4. Puspitasari HP et al. Pharmacists’ and consumers’ viewpoints on counselling on prescription medicines in Australian community pharmacies. *Int J Pharm Pract* 2010; 18: 202–208.
5. Bagg M et al. Older people’s attitudes towards their regular medicines. *J Prim Health Care* 2013; 5: 234–242.
6. Raynor DK et al. Consumer medication information in the United States, Europe, and Australia: a comparative evaluation. *J Am Pharm Assoc* 2007; 47: 717–724.
7. Fuchs J et al. A survey of package inserts use by patients. *Hosp Pharm* 2005; 29–31.
8. Wallace LS et al. Suitability and readability of consumer medical information accompanying prescription medication samples. *Patient Educ Couns* 2008; 70: 420–425.
9. Chan HW et al. What is the quality of drug safety information for patients: an analysis of REMS educational materials. *Pharmacoepidemiol Drug Saf* 2018; 27: 969–978.
10. Eysenbach G. Medicine 2.0: social networking, collaboration, participation, apomediation, and openness. *J Med Internet Res* 2008; 10: e22.
11. Peterson-Clark G et al. Consumer use of the internet for medicines information. *Int J Pharm Pract* 2004; 12: 185–190.
12. Househ M et al. Empowering patients through social media: the benefits and challenges. *Health Informatics J* 2014; 20: 50–58.
13. Australian Market and Social Research Society. *Code of Professional Behaviour*. Glebe, NSW, Australia: Australian Market and Social Research Society, 2017.
14. Shiffman S et al. Consumer understanding of prescription drug information: an illustration using an antidepressant medication. *Ann Pharmacother* 2011; 45: 452–458.
15. Olsen AK, Whalen MD. Public perceptions of the pharmaceutical industry and drug safety: implications for the pharmacovigilance professional and the culture of safety. *Drug Saf* 2009; 32: 805–810.
16. Ding EL et al. Sex differences in perceived risks, distrust, and willingness to participate in clinical trials: a randomized study of cardiovascular prevention trials. *Arch Intern Med* 2007; 167: 905–912.
17. Linn AJ et al. Patients’ online information-seeking behavior throughout

**Funding**

The study was funded by Bayer Australia Limited.

**Acknowledgements**

The authors thank Catherine Donovan for her contribution to design of the survey and comments on early versions of this manuscript. Medical writing support was funded by Bayer Australia Limited, in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).

**Author contributions**

MS made a substantial contribution to the conception and design of the survey. BB provided statistical advice and analysis. All authors contributed to the interpretation of the data. All authors critically revised the manuscript for important intellectual content and approved the final version to be published. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriate investigated and resolved.
treatment: the impact on medication beliefs and medication adherence. *Health Commun* 2019; 34: 1461–1468.
18. Narhi U. Sources of medicine information and their reliability evaluated by medicine users. *Pharm World Sci* 2007; 29: 688–694.
19. Carpenter DM et al. The effect of conflicting medication information and physician support on medication adherence for chronically ill patients. *Patient Educ Couns* 2010; 81: 169–176.
20. Langille M et al. Systematic review of the quality of patient information on the internet regarding inflammatory bowel disease treatments. *Clin Gastroenterol Hepatol* 2010; 8: 322–328.
21. Ziegler DK et al. How much information about adverse effects of medication do patients want from physicians? *Arch Intern Med* 2001; 161: 706–713.
22. Knox C et al. Patient understanding of drug risks: an evaluation of medication guide assessments. *Pharmacoepidemiol Drug Saf* 2015; 24: 518–525.
23. Hamrosi KK et al. Pharmacist and general practitioner ambivalence about providing written medicine information to patients – a qualitative study. *Res Social Adm Pharm* 2013; 9: 517–530.
24. Hamrosi KK et al. Pharmacist, general practitioner and consumer use of written medicine information in Australia: are they on the same page? *Res Social Adm Pharm* 2014; 10: 656–668.
25. Pires C et al. Factors influencing subjects’ comprehension of a set of medicine package inserts. *Int J Clin Pharm* 2016; 38: 888–898.
26. Bitonti M et al. The effect of counseling on willingness to use a hypothetical medication and perceptions of medication safety. *Res Social Adm Pharm* 2018; 14: 295–302.
27. Hamrosi KK et al. Enhancing provision of written medicine information in Australia: pharmacist, general practitioner and consumer perceptions of the barriers and facilitators. *BMC Health Serv Res* 2014; 14: 183.
28. Fortnum H et al. Survey to assess public awareness of patient reporting of adverse drug reactions in Great Britain. *J Clin Pharm Ther* 2012; 37: 161–165.
29. Robertson J, Newby DA. Low awareness of adverse drug reaction reporting systems: a consumer survey. *Med J Aust* 2013; 199: 684–686.
30. Wei M-H. The associations between health literacy, reasons for seeking health information, and information sources utilized by Taiwanese adults. *Health Educ J* 2013; 73: 423–434.
31. Al Dweik R et al. Factors affecting patient reporting of adverse drug reactions: a systematic review. *Br J Clin Pharmacol* 2017; 83: 875–883.
32. de Vries ST et al. Interest in a mobile app for two-way risk communication: a survey study among European Healthcare Professionals and Patients. *Drug Saf* 2018; 41: 697–712.
33. Inacio P et al. The value of patient reporting to the pharmacovigilance system: a systematic review. *Br J Clin Pharmacol* 2017; 83: 227–246.

**Supporting information**

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site:

Table S1. Bayer patient safety study question text and responses.